11 June 2015

RPL554 Phase 2a trial started; headline data expected Q1 2016

Read more

8 June 2015

RPL554 MAD study complete

VERONA PHARMA PLC - RPL554 MAD study complete

Read more

8 June 2015

RPL554 MAD study in healthy volunteers confirms excellent tolerability; dosing of COPD patients commences

Read more

18 May 2015

Director/PDMR Shareholding

Verona Pharma plc

Read more

13 May 2015

2014 Annual Report and Accounts and Notice of AGM

Verona Pharma plc

Read more

12 May 2015

Final Results

VERONA PHARMA PLC - Final Results

Read more

5 May 2015

Notice of Results

VERONA PHARMA PLC - Notice of Results

Read more

14 April 2015

Presentation at the Asthma and COPD Conference

VERONA PHARMA PLC - Presentation at the Asthma and COPD Conference

Read more

23 March 2015

Interim results from new RPL554 trial

VERONA PHARMA PLC - Interim results from new RPL554 trial

Read more

3 March 2015

Trading and Development Programme Update

VERONA PHARMA PLC - Trading and Development Programme Update

Read more

Innovative Therapies for Respiratory Care

See the 2017 Verona Pharma corporate video 2017

Runtime: 04:05

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us